Luke Timmerman sets the standard for excellence in biotech journalism. His brand of tough, intellectually honest, independent reporting is essential for our industry.
There are a lot of writers commenting on the biopharmaceutical industry. Only a few really matter. Luke has proven himself to be one of them.
Luke has the rare ability to ask just the right questions to get underneath the standard “company line” and provide real insight.
Timmerman is always ahead of the game.
Biotech social media is easy to obtain, but is a firehose of data, information, and speculation. The savvy professional needs less noise and more actionable signal. Luke Timmerman finds and writes about that signal.
Luke’s ability to blend the implications of science with the exigencies of business creates an idiosyncratic and insightful read. Biotech has grown up into a real, and responsible, industry and I am curious to get Timmerman’s views on how to keep up the innovation, frame necessary social dialogues, inspire youngsters, and really ‘go global’.
Luke Timmerman knows the deep secret of biotech: success requires technology plus people.
Luke has an uncanny ability to get to the heart of an issue, put it in a broader context and reveal what really matters. He makes the people and topics he covers come to life.
Luke reports on biotech with context like no other. The phrase “What did you think about what Luke wrote?” will once again be a regular comment in hallways and meetings.
Venture investors excel when they have asymmetric information flow. The Timmerman Report will be a key part of our diligence and understanding of not just biotech, but overall healthcare.
Quality information is invaluable in biotech. Luke Timmerman—through thoughtful research articles, timely and accurate coverage of the news, and great interviews—really delivers value.
When I was unemployed, I gained valuable insight from Luke Timmerman’s reporting. I learned which factors outside the lab can impact biotech hiring. I was able to start looking for jobs where they actually are.
Luke’s early coverage of PacBio helped propel our work into the mainstream media, helping secure further support for our research.
One key to investing is in knowing what is coming next. Timmerman’s reporting gave me a year head start on the importance of CAR-T immunotherapy, which was a huge benefit.
Smart, insightful, analytical—even occasionally funny—reporting. No click bait stunts.
Luke’s analysis of drug research and development help set the agenda for what industry professionals discuss.